Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q4 earnings. Here is a breakdown of the information Annexon Biosciences, Inc. presented to ...

GBS is a rare, neuromuscular emergency that affects at least 150,000 people worldwide each year, with no FDA-approved therapy. The life-altering consequences of GBS were recently detailed in a new ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory ...

Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, ...

Joint injury induces rapid and sustained diversification of resident and infiltrating synovial macrophage phenotypes, underpinning osteoarthritis-associated synovitis.

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

The Economic Mobility Pathways Pilot (EMPP) is a program for skilled refugees and displaced people looking to work permanently in Canada. The EMPP: helps skilled refugees and other displaced people ...

Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, United States ...

Recognition Molecules of the Classical and Lectin Complement Pathways The described mechanisms of activation of the CP and LP illustrate two of the key characteristics of the complement cascade.